Compositions and methods for the treatment of sexual dysfunction

Abstract

Described herein are pharmaceutical compositions for the treatment of sexual dysfunction in an individual. In some embodiments, the pharmaceutical composition includes a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine. In one embodiment, the amino acid is arginine. In one embodiment, the prolactin variant further comprises an N-terminal deletion. In one embodiment, the prolactin variant is conjugated to a H(OCH2CH2)nOH molecule (e.g., n equals any number from 1 to 6). In some embodiments, the pharmaceutical composition is delivered to the individual by a microneedle patch or an inhalable formulation.

Dependencies are inferred from the claim text.